Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance - Johnathan Oh; Minal Barve; Neil Senzer; Phylicia Aaron; Luisa Manning; Gladice Wallraven; Ernest Bognar; Laura Stanbery; Staci Horvath; Meghan Manley; John Nemunaitis; Adam Walter; et al. (Elsevier, 2020)